EDITORIAL

Editorial on the contribution of V. Labarque, entitled “New and emergent treatment options in sickle cell disease”

BJH - volume 12, issue 7, november 2021

P. Zachée MD, PhD

(BELG J HEMATOL 2021;(7):288-9)

Read more

Management of systemic mastocytosis: A heterogeneous disease requiring a correct diagnosis and adapted treatment

BJH - volume 10, issue 7, november 2019

J. Depaus MD

Editorial for the contribution of T. Goos et al., entitled: A single-center retrospective study of patients with systemic mastocytosis at University Hospital Leuven
BELG J HEMATOL 2019;10(7):265-76)

(BELG J HEMATOL 2019;10(7):264)

Read more

NGS: investing in deeper evaluation and optimised therapeutic decisions in myeloid neoplasms

BJH - volume 10, issue 6, october 2019

P. Vandenberghe MD, PhD

Editorial for the contribution of E. Van Valckenborgh et al., entitled: Diagnostic testing in myeloid malignancies by next-generation sequencing: recommendations from the Commission Personalised Medicine (BELG J HEMATOL 2019;10(6):241–9)

(BELG J HEMATOL 2019;10(6):229–30)

Read more

How to isolate and analyse microvesicles in human samples?

BJH - volume 4, issue 1, march 2013

B. Chatelain PharmD, C. Chatelain MD, F. Mullier PhD, PharmD, J-M. Dogné PhD, PharmD, N. Bailly

(BELG J HEMATOL 2013;1:9–10)

Read more

Chronic lymphocytic leukaemia: accessibility for Belgian patients to recommended treatments?

BJH - volume 3, issue 4, december 2012

A. Bosly MD, PhD

Editorial for the contribution of A. Janssens et al, entitled “BHS guidelines for the treatment of chronic lymphocytic leukaemia anno 2012”

Read more
X